Copy to clipboard 
RoosterBio and Tissue Regeneration Therapeutics (TRT) will collaborate to develop TRT’s human umbilical cord-derived mesenchymal stem/stromal cell (hUC-MSCs) technology for commercialization to the entire regenerative medicine marketplace. This set of biological tools will be integrated with RoosterBio’s product formats.
Per agreement terms, RoosterBio obtains an exclusive worldwide license to TRT’s patent estate related to manufacture and global sale of human umbilical cord-derived MSCs. RoosterBio will apply their manufacturing expertise and hMSC product format configurations drive the product development using TRT’s patented technology.
TRT’s patent estate includes eight issued patents and several patent applications pending that cover the composition of matter, method of manufacturing and method of use related to hUC-MSCs. TRT also gains access to RoosterBio’s manufacturing technology platform, supply chain and bioprocess media at significant discounts.
Margot Connor, RoosterBio’s CEOnoted, “The products that we launch from this initiative will complement our current hMSC product portfolio that includes bone marrow-derived and adipose-derived cellular technology, enabling us to reach more customers around the globe.”
RoosterBio is a stem cell tools and technology company focused on accelerating development of sustainable regenerative medicine. Products are high volume, affordable and well-characterized adult hMSCs paired with highly engineered media systems. RoosterBio has simplified and standardized how stem cells are purchased, expanded and used in development, leading to time and costs savings for customers.
Source: RoosterBio, Inc.
